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Abstract
Background: Feeding behavior is regulated through an intricate array of anorexic and orexigenic hormones acting
on the central nervous system (CNS). Some of these hormones may have differential effects in males and females,
effects potentially attributed to actions of gonadal steroids, especially estrogens. Central stimulation of the
glucagon-like peptide-1 (GLP-1) receptors reduces feeding and food-reward behavior by acting on CNS regions
important for the anorexic actions of estrogens. Thus, we propose that the action of GLP-1 on food intake and
reward may differ between sexes.
Methods: Male and female rats were centrally injected with the GLP-1 analog exendin-4 (Ex4) in a non-deprived or
food-restricted state; reward behavior was measured in a progressive ratio operant conditioning task. Intake of
chow and palatable food were also measured. To determine if sex differences in the actions of Ex4 are due to
interactions with estrogens, Ex4 treatment was preceded by treatment with a nonselective estrogen receptor-α
(ERα) and ERβ or ERα-selective antagonist.
Results: Central injection of Ex4 revealed increased reward behavior suppression in females, compared to males, in
the operant conditioning task. This increase was present in both non-deprived and food-restricted animals with
larger differences in the fed state. Intake of chow and palatable food, after Ex4, were similar in males and females.
Food reward, but not food intake, effect of Ex4 was attenuated by pretreatment with ER antagonist in both sexes,
suggesting that estrogens may modulate effects of Ex4 in both sexes. Furthermore, central pretreatment with
ERα-selective antagonist was sufficient to attenuate effects of Ex4 on reward.
Conclusions: Collectively, these data reveal that females display much higher sensitivity to the food reward impact
of central GLP-1 receptor activation. Surprisingly, they also demonstrate that central ERα signaling is necessary for
the actions of GLP-1 on food-reward behavior in both sexes.
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Background
Sex is a basic biological variable that influences physi-
ology and disease. Despite the overrepresentation of
women in diseases resulting from disordered eating [1, 2],
few preclinical studies have a clear focus to explore the
neurobiology and physiology of food intake regulation in
females. This sex gap is symptomatic of what is seen in
preclinical medical research overall. According to a recent
review of preclinical publications [3], nearly two out
of three papers did not even report the sex of the an-
imals used in the study. Nevertheless, physiology and
pathophysiology of feeding behavior differ in male
and female animals or humans. Recent data suggest
that the female brain responds differently to different
food intake regulating signals [4–6].
Glucagon-like peptide-1 (GLP-1) and its receptors
have emerged as a successful therapeutic target for treat-
ment of type-2 diabetes [7, 8]. The usage of GLP-1-
based therapy is increasing at a fast pace; however, some
aspects of GLP-1 function, especially pertaining to its
role in the central nervous system (CNS), remain unex-
plored. Considering the increasing amount of patients
receiving this treatment [9, 10], there is a certain
urgency to develop a better understanding of the action
of GLP-1 and its analogs on the CNS. Increasingly, more
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evidence is pointing to the CNS as a major target for
GLP-1 [11]. In fact, derived from preproglucagon, GLP-1
is produced not only in the periphery (intestine, pancreas)
but also in the CNS, primarily by neurons located in the
nucleus of the solitary tract (NTS). Central injections of
GLP-1 receptor (GLP-1R) agonists potently decrease food
intake; this anorexic action has been ascribed to the
hypothalamic and brainstem GLP-1R expressing targets
[11–15]; the same CNS regions are implicated for the
anorexic action of estrogens [16–19], providing neu-
roanatomical grounds for a potential interaction between
GLP-1R activation, sex, and estrogens proposed here.
Food intake is regulated not only from brain regions
traditionally recognized for their role in homeostatically
driven feeding, like the hypothalamus and the hindbrain,
but also from extra-homeostatic areas that control re-
warding aspects of eating [20, 21]. Food reward is an im-
portant component in the development of overeating
and obesity [22] and can be divided in two components,
“liking” and “wanting,” as previously described by
Berridge et al. [23, 24]. Wanting is associated with in-
centive salience and motivation for a certain type of food
and is often coupled to stimuli, which can trigger a de-
sire to acquire or work for the rewarding component.
Liking on the other hand is more commonly associated
with palatability. Though these two systems are closely
linked, they also have the ability to act independently of
each other, and via separate neural pathways, to modu-
late reward [23]. The wanting component of food reward
is closely linked to the mesolimbic neurocircuitry, espe-
cially the ventral tegmental area (VTA) and its dopamin-
ergic projections to the nucleus accumbens (NAc) [25].
GLP-1Rs and GLP-1-carrying fibers can also be found in
these areas of the brain, involved in motivated behavior
and addiction [26]. GLP-1 can change reward behavior
in males [27–31]. However, little is known about GLP-1-
driven food-reward control in females. Here, we deter-
mined whether there are sex differences in the sensitivity
of food reward, more specifically food motivation and
consumption of palatable food, and chow intake behav-
ior to central GLP-1R activation.
Methods
Animals
Female and male Sprague-Dawley rats (160–200 g at
arrival, and mean body weights of 260 and 480 g for
females and males, respectively, during testing, Charles
River, Germany) were housed in a 12-h light/dark cycle,
in individual cages with ad libitum access to chow and
water, unless otherwise specified. Female rats presented
with normal 4- to 5-day estrous cycles throughout the
experimental testing. However, this study was not de-
signed to analyze any potential impact of cycling. All
testing was conducted during the light cycle. All studies
were carried out with ethical permissions from the Animal
Welfare Committee of the University of Gothenburg, in
accordance with legal requirements of the European
Community (Decree 86/609/EEC). All efforts were made
to minimize suffering.
Drugs
Exendin-4, angiotensin II, ICI 182, 780 [32], and MPP
dihydrochloride (MPPd) were purchased from Tocris
(Bristol, UK). Ex4 and angiotensin II were dissolved in
artificial cerebral spinal fluid (aCSF, vehicle for central
injection), and ICI and MPPd were dissolved in aCSF
with 10 and 20 % DMSO, respectively. All drugs were
stored as aliquots at −20 °C.
Operant conditioning
The progressive ratio operant conditioning schedule is a
procedure used to analyze motivated behavior (reward
wanting, often compared to the human experience of
craving) and measures the amount of work or effort that
a subject is willing to put in to obtain a reward, in this
case rewarding food in the form of sucrose, and it there-
fore mainly measures the wanting component of food
reward. Operant conditioning training was conducted in
rat conditioning chambers (Med-Associates, Georgia,
VT, USA) as described previously [27, 33] in ad libitum
fed rats. Rats were trained to press a lever for a 45-mg
sucrose pellet. Training was conducted in four stages:
rats were first trained on the fixed ratio 1 (FR1) schedule
in 30-min sessions (single press on the active lever re-
sulted in the delivery of one sucrose pellet), followed by
FR3 and FR5 (3 and 5 presses per pellet, respectively),
where a minimum of 30 responses per session on the
active lever was required for advancement to the next
schedule, concluding with progressive ratio conditioning
until stable responding was achieved. Each progressive
ratio session lasted for 1 h. Responding was considered
stable when the number of pellets earned per session did
not differ more than 15 % between three consecutive
sessions. All operant response testing was performed
after the responses stabilized. All drug injections and
testing were performed during the light cycle, starting
2 h after lights-on as specified below, and testing com-
menced 20 min after drug injection. Injections were
done in a counterbalanced, Latin square design, with at
least 48 h separating each injection condition.
Brain cannulation
Due to variations in body weight between male and fe-
male subjects, in addition to differential fat pad location
and size [34], along with the fact that Ex4 can cross the
blood-brain barrier [35], direct brain administration was
chosen for all substances tested in order to avoid the po-
tential confounding effects from these variations. As a
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result, our experiments are not relevant to effects solely
mediated by peripheral GLP-1R. Rats were implanted
with a guide cannula targeting the lateral ventricle [36]
(26 gauge; Plastics One, Roanoke, VA): ±1.6 from the
midline, 0.9 mm posterior to bregma, and 2.0 mm ven-
tral to skull, with an injector aimed 4.0 mm ventral to
the skull under ketamine anesthesia. The cannulas were
attached to the skull with dental acrylic and jeweler’s
screws and closed with an obturator as described previ-
ously [37]. Placement was verified with the angiotensin
II drinking test. Angiotensin II was injected at a dose of
20 ng in 2 μL of aCSF, and water intake was measured
throughout the following 30 min. Rats who consumed a
minimum of 5 mL of water within the measured time
period were considered to have correctly positioned
cannulas.
Effects of central Ex4 in non-deprived males and females
on food-motivated behavior and food intake
Male and female rats were injected with Ex4 (0.1 or
0.3 μg/μL) or vehicle into the left ventricle (LV). Doses
were previously shown to reduce food motivation in
food-restricted male rats [27]. Twenty minutes after in-
jection, the rats were placed in the operant conditioning
chambers for a 1-h testing period. Testing was per-
formed in a non-deprived state 2 h following the dark
cycle period where rats had ad libitum access to chow.
After testing, the rats were returned to their home cages
and given access to palatable food—peanut butter. After
1 h, the amount of consumed peanut butter was mea-
sured and the rats received normal chow for the remain-
der of the 24-h period.
Effect of central Ex4 in overnight food-restricted males
and females on food-motivated behavior and food intake
Rats were food-restricted overnight to approximately
50 % of their normal intake. On the following day, rats
of each sex were injected with Ex4 (0.3 μg/μL) or vehicle
and the operant conditioning test was performed 20 min
after injection for 60 min. Peanut butter intake and
chow intake were measured as described above.
Effects of central estrogen blockade on male and female
food-motivated behavior after Ex4 treatment
Food-restricted male and female rats received injections
of the estrogen receptor (ER) antagonist ICI (10 μg/μL)
[38] or vehicle into the left ventricle (LV) prior to injec-
tion of Ex4 (0.3 μg/μL) or vehicle in this area. Food re-
striction and the higher Ex4 dose were chosen in order
to induce reliable reward behavior reduction in both
sexes. Operant conditioning, intake of peanut butter, and
chow consumption were measured as described above.
Effects of central administration of the ERα-antagonist on
male and female food-motivated behavior after Ex4
treatment
Overnight food-restricted rats were injected with 1.4 μg/μL
[39] of the estrogen receptor-α (ERα) (Esr1)—antagonist
MPPd or vehicle, accompanied by injection of 0.3 μg/μL
Ex4 or vehicle, into the LV. Operant conditioning, intake
of peanut butter, and chow consumption were measured as
described above.
Statistical analysis
All the data are presented as mean ± standard error of
the mean (SEM). Statistical significance was analyzed
using Student’s t test or one- and two-way ANOVA,
when appropriate, with Sidak’s or Holm-Sidak’s post hoc
tests (GraphPad Software, Inc., San Diego, CA). p values
lower than 0.05 were considered statistically significant.
Results
Effect of central Ex4 treatment on reward and food intake
in non-deprived males and females
To investigate potential differences in the effects of
central Ex4 treatment between males and females, rats
of both sexes were tested using a progressive ratio
reinforcement schedule after administration of Ex4 (0.01
or 0.03 μg/μL) or vehicle. Two-way repeated measures
ANOVA revealed a significant reduction in sucrose re-
wards earned, and lever presses for sucrose, at both
doses of Ex4 in female, but not male, rats (Holm-Sidak’s
multiple comparisons test, p < 0.0001; Fig. 1a, c). The
main effect of drug treatment was significant for both
rewards earned and number of lever presses for rewards
(F(2, 108) = 19.25, p < 0.0001; F(2, 108) = 15.91, p < 0.0001).
The main effect of sex on rewards earned and lever
presses was not significant (F(1, 108) = 1.790, p > 0.05;
F(1, 108) = 3.717, p > 0.05, respectively). Importantly,
there was a significant interaction between these two
factors (F(2, 108) = 10.46, p < 0.0001; F(2, 108) = 9.195,
p < 0.001). Data displayed as sucrose rewards earned and
active lever presses in percent of vehicle value revealed
significant differences for both parameters at both doses
of Ex4 between males and females (p < 0.05, Fig. 1b;
p < 0.05, Fig. 1d). Two-way ANOVA also revealed a
significant effect of sex (F(1, 108) = 25.56, p < 0.0001;
F(1, 108) = 17.02, p < 0.0001) and a significant interaction
between sex and treatment (F(2,108) = 7.610, p < 0.001;
F(2,108) = 4.424, p < 0.05).
Central GLP-1R stimulation led to a significant de-
crease in peanut butter consumption compared to con-
trols in both sexes (two-way ANOVA, Holm-Sidak’s
multiple comparisons test, p < 0.001 and p < 0.0001 for
females for the low and high dose of Ex4, respectively,
and p < 0.0001 for males for both doses of Ex4; Fig. 1e).
Two-way repeated measures ANOVA indicated that the
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main effect of sex on peanut butter consumption was not
significant (F(1, 108) = 2.088, p > 0.1). The effect of drug
treatment, however, was significant (F(2, 108) = 36.38,
p < 0.0001) though there was not a significant inter-
action between these two factors (F(2, 108) = 0.2951,
p > 0.1). Data expressed as percent of vehicle value
revealed a significant effect of drug treatment (F(2, 108) =
130.1, p < 0.0001), but not the effect of sex (F(1, 108) =
0.4864, p > 0.1; Fig. 1f) or interaction between these
parameters (F(2, 108) = 3.026, p > 0.05).
To investigate if 1 h peanut butter consumption is in-
fluenced by the experimental setup (the timing of the
Fig. 1 In non-deprived animals, central GLP-1R stimulation specifically decreases food-motivated behavior in females but not males. Ex4 injection
into the LV significantly reduced sucrose rewards earned (a), and active lever presses for reward (c) in female but not male subjects. Sucrose
rewards (b) and active lever presses (d) were also significantly lower in females compared to males after Ex4 treatment, at both doses, analyzed
as percent relative to vehicle value. Central GLP-1R agonist treatment significantly reduced peanut butter consumption in both males and females
(e), with no significant differences between the two sexes (f). Chow consumption was reduced in males and females after Ex4 treatment (g); no
significant differences were present between sexes at either dose of the agonist (h). Chow and peanut butter consumption are displayed in
grams. Data are expressed as mean ± SEM. n = 20 (females) and 18 (males) per treatment group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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test relative to injections or the fact that it is preceded
by the operant task), an additional group of males
received Ex4 injections (0.3 μg/μL) or vehicle, in a non-
deprived state, and peanut butter consumption was mea-
sured 20 min after injection for 60 min (the same time
point as operant conditioning testing was conducted).
One-hour peanut butter consumption was significantly
reduced in Ex4-treated male subjects compared to con-
trols (Student’s t test, p < 0.05, data not shown) at this
time point. The size of the effect was comparable to the
effect obtained when testing was conducted after PR, in-
dicating that 1 h intake after PR testing was not affected
by the experimental design.
In addition to peanut butter, Ex4 treatment led to a sig-
nificant dose-dependent reduction in chow intake after
24 h, in both male and female rats (two-way ANOVA,
Holm-Sidak’s multiple comparisons test, p < 0.0001 for
both doses of Ex4, in males and females; Fig. 1g). The
main effect of drug treatment was significant (two-way
ANOVA, F(2, 108) = 118.5, p < 0.0001). Two-way repeated
measures ANOVA also revealed a significant difference
between males and females in both the main effect of sex
(F(1, 108) = 21.01, p < 0.0001) as well as interaction between
sex and drug treatment (F(2, 108) = 9.590, p < 0.001).
Comparison of chow consumption relative to vehicle
revealed a significant effect of treatment (F(2, 108) = 149.5,
p < 0.0001; Fig. 1h), but not sex (F(1, 108) = 1.698, p > 0.1),
and there was no significant interaction between these
two factors (F(2, 108) = 1.051, p > 0.1).
Effect of central Ex4 treatment on reward and food intake
in food-restricted males and females
Due to the absence of effect of Ex4 on food-motivated
behavior in non-food deprived males, an effect which
has previously been established for fasted males, add-
itional experiments in a food-restricted state were neces-
sary to validate the experimental setup and to investigate
potential differences in the action of Ex4 between sexes
in different hunger states. Operant conditioning testing
as well as food intake measurements were therefore con-
ducted in overnight food restricted animals using only
the higher concentration of Ex4. Under these conditions,
Ex4 significantly decreased the amount of sucrose re-
wards earned in both males and females (Holm-Sidak’s
multiple comparisons test, p < 0.0001 and p < 0.05 for fe-
males and males, respectively; Fig. 2a). While the main
effect of drug treatment was significant (two-way
ANOVA, F(1, 34) = 38.41, p < 0.0001), the main effect of
sex was not (F(1, 34) = 1.219, p > 0.1). Importantly, there
was also a significant interaction between these two fac-
tors (F(1, 34) = 4.447, p < 0.05). Though significant in both
groups, females had a larger reduction in rewards earned
than males (sucrose rewards earned as percent of vehicle
value, p < 0.01; Fig. 2b). In the restricted condition, lever
pressing for sucrose rewards reached significance in the
female group after analysis using two-way ANOVA ana-
lysis (p < 0.001; Fig. 2c). Though the effect of treatment
was significant (F(1, 34) = 21.66, p < 0.0001), there was no
significant effect of sex (F(1, 34) = 1.943, p > 0.1) or
interaction of sex and drug treatment (F(1, 34) = 2.725,
p > 0.1). Additionally, a significant difference was present
between active lever press counts for restricted males
and females (presses in percent of vehicle, p < 0.01;
Fig. 2d).
In restricted animals, Ex4 treatment led to a significant
reduction in 1 h peanut butter consumption in both
sexes (two-way ANOVA, Holm-Sidak’s multiple compar-
isons test, p < 0.001 for males and females; Fig. 2e). The
main effect of drug treatment was significant (two-way
ANOVA, F(1, 34) = 44.26, p < 0.0001). The main effect of
sex was non-significant (F(1, 34) = 1.545, p > 0.1). There
was no significant interaction between these two factors
(F(1, 34) = 0.00183, p > 0.1). There was, however, a differ-
ence in peanut butter consumption between male and
female Ex4-treated groups when analyzed as percent
peanut butter consumed relative to the amount con-
sumed after vehicle injection (p < 0.05; Fig. 2f ).
Ex4 treatment also led to a significant reduction in 24 h
chow consumption, compared to controls, in both re-
stricted males and females (two-way ANOVA, Holm-
Sidak’s multiple comparisons test, p < 0.001 and p < 0.0001
for females and males, respectively; Fig. 2g). Two-way
ANOVA revealed significance in all measures, including
the main effect of sex (F(1, 34) = 18.46, p < 0.001), the main
effect of drug treatment (F(1, 34) = 85.50, p < 0.0001),
and the interaction between these two measures
(F(1, 34) = 10.14, p < 0.01). However, no differences
were found between Ex4-treated males and females when
displayed as percent chow consumed compared to vehicle
(Fig. 2h).
Effect of estrogen blockade on the actions of Ex4 on
reward in food-restricted rats
To explore the impact of estrogens on the actions of
Ex4, the estrogen antagonist ICI was administered cen-
trally along with Ex4 into fasted male and female rats.
Two-way repeated measures ANOVA revealed a signifi-
cant difference in the main effect of sex (F(3, 98) = 14.71,
p < 0.001) and effect of drug treatment (F(3, 98) = 14.43,
p < 0.0001). A significant interaction between the two
factors was also detected (F(3, 98) = 4.014, p < 0.01).
Pretreatment with ICI attenuated the Ex4-induced food
reward suppression in female rats. After the combined
treatment, the amount of sucrose rewards earned was
therefore no longer statistically significant compared to
controls (Fig. 3c). Interestingly, similar effects of the com-
bined treatment on sucrose rewards earned were also
present in males (Fig. 3a). For lever presses, two-way
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Fig. 2 Ex4 treatment in overnight food-restricted rats leads to a larger reduction in food-motivated behavior in females than males. After overnight
food restriction, central Ex4 treatment reduced sucrose rewards earned in both males and females (a), an effect that was larger in females (b). Active
lever presses were significantly reduced by Ex4 treatment in female subjects; a trend for reduction was present in male subjects but it did not reach
statistical significance (c). Lever presses after Ex4 treatment in males and females analyzed as percent of vehicle treatment also revealed a significantly
larger reduction in female subjects (d). Peanut butter consumption was significantly reduced in both sexes (e) with a slightly larger
response to Ex4 in females (f). Twenty-four hour chow consumption was reduced in both males and females after GLP-1R agonist injection (g); no
significant differences were found in chow intake between the two sexes (h). Chow and peanut butter consumption are displayed in grams. Data are
expressed as mean ± SEM. n = 10 (females) and 9 (males) per treatment group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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ANOVA indicated a significant effect of sex (F(1, 98) =
25.87, p < 0.0001) and effect of drug treatment (F(3, 98) =
13.87, p < 0.0001). Importantly, there was also a significant
interaction between the two factors (F(3, 98) = 6.792,
p < 0.001). ICI treatment in females led to an attenuation
of the reduction of active lever presses for sucrose after
Fig. 3 Central estrogen blockade attenuates the effects of Ex4 on food-motivated behavior. Concurrent administration of the selective estrogen
antagonist ICI and Ex4 attenuated the reduction in sucrose rewards earned in females (c) and males (a) compared to Ex4 treatment alone, although
this effect did not reach significance. Reduction of active lever presses for sucrose was also attenuated in both sexes after ICI treatment (b, d). The
number of sucrose rewards earned for males and females combined was reduced after central Ex4 injection (e); this effect was attenuated after ICI
treatment. Combined results for males and females also demonstrate a significant reduction in lever presses for sucrose after central GLP-1R stimulation;
attenuation by the ICI treatment did not reach statistical significance (f). Data are expressed as mean ± SEM. n= 10 (females) and 18 (males) per treatment
group. *p < 0.05, **p< 0.01, ****p < 0.0001
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central GLP-1R stimulation (Fig. 3d). In males, the re-
duced amount of active lever presses for sucrose did not
reach statistical significance after Ex4 treatment, although
interestingly, combination of Ex4 with the antagonist
treatment did lead to an increase in the amount of lever
presses compared to Ex4 treatment alone (Fig. 3b). When
results of males and females are combined due to similar
trend in response pattern, a significant difference in re-
wards earned (one-way ANOVA, F(3, 102) = 9.633, p < 0.05;
Fig. 3e), but not active lever presses for sucrose (Fig. 3f),
between Ex4- and Ex4/ICI-treated rats is detected. ICI
treatment alone did not have any significant effects on
reward-related behavior in this experiment. One male rat
and three female rats did not finish the study due to dis-
lodged or blocked cannula.
Two-way repeated measures ANOVA indicated that
the main effect of sex (F(1, 63) = 0.8913, p > 0.1) was not
significant. Drug treatment (F(3, 63) = 4.682, p < 0.01) was
significant. A significant interaction between these two
factors was not found (F(3, 63) = 0.3939, p > 0.1). Treat-
ment with Ex4 alone, or in combination with the estro-
gen antagonist ICI, led to a significant reduction in
peanut butter consumption after 1 h in females (one-
way ANOVA, F(3, 33) = 4.242, p < 0.05; Fig. 4c), but not in
males (F(3, 30) = 1.142, p > 0.1; Fig. 4a). Chow consump-
tion was significantly different, both regarding the dif-
ferences in the effect of sex (F(1, 97) = 17.73, p < 0.0001)
and the main effect of drug treatment (F(3, 97) = 1.197,
p < 0.001). A significant interaction between these two
factors was not found (F(3, 97) = 0.6991, p > 0.1). Twenty-
four hour chow consumption was reduced after Ex4 treat-
ment in both male and female subjects (one-way ANOVA,
F(3, 66) = 4.139, p < 0.05; Fig. 4b, F(3, 31) = 9.230, p < 0.001;
Fig. 4d, for males and females, respectively). In contrast to
peanut butter consumption, ICI treatment attenuated
Ex4-induced food intake reduction in females, but not in
males, resulting in an increased amount of chow intake
consumed during the 24-h period (Fig. 4b, d).
Effects of central administration of the ERα-antagonist
MPPd on male and female food-motivated behavior after
Ex4 treatment
For sucrose rewards earned, two-way ANOVA re-
vealed a significant difference in the main effect of
sex (Holm-Sidak’s multiple comparisons test, F(1, 56) =
7.319, p < 0.01) and effect of drug treatment (F(3, 56) =
13.98, p < 0.0001). A significant interaction between these
two factors was not found (F(3, 56) = 0.5209, p > 0.1). As
shown previously, Ex4 significantly decreased the amount
of sucrose rewards earned in both male and female
rodents in the operant conditioning task (one-way
ANOVA, F(3, 28) = 4.750, p < 0.5; Fig. 5a, F(3, 28) = 10.04,
p < 0.001; Fig. 5c, for males and females, respectively).
Coinciding treatment with MPPd attenuated the effects of
Ex4 in both sexes (Fig. 5a, c). Two-way repeated measures
ANOVA revealed that the main effect of sex (F(1, 56) =
9.483, p < 0.01) and drug treatment (F(3, 56) = 10.36,
p < 0.0001) were significant for active lever presses. There
was, however, no interaction between these two factors
(F(3, 56) = 1.777, p > 0.1). Active lever presses for sucrose
were significantly decreased in females after Ex4 treatment
(one-way ANOVA, F(3, 28) = 7.328, p < 0.01; Fig. 5d), but
not in males (Fig. 5b). The effects of Ex4 on lever presses
were also attenuated after MPPd treatment in females and
an increase in presses was also present in males, though
this increase was not significant (Fig. 5d, b). Combined re-
sults for males and females showed a significant increase
in sucrose rewards earned after MPPd/Ex4 treatment
compared to Ex4 treatment alone (one-way ANOVA, F(3,
60) = 12.92, p < 0.05; Fig. 5e). The attenuation of MPPd/
Ex4 administration on active lever presses in males and
females combined, however, did not reach significance (5F).
Two-way repeated measures ANOVA indicated that
the main effect of sex was not significant (F(1, 56) = 1.413,
p > 0.1) for 1-h peanut butter consumption. The main
effect of drug treatment was significant (F(3, 56) = 20.13,
p < 0.0001). A significant interaction between these two
factors was not found (F(3, 56) = 0.7364, p > 0.1). MPPd
injection did not affect the action of Ex4 on peanut but-
ter consumption which remained significantly reduced
compared to vehicle in both males and females (one-way
ANOVA, F(3, 28) = 10.21, p < 0.01; Fig. 6a, F(3, 28) = 10.74,
p < 0.001; Fig. 6c, for males and females, respectively).
Two-way repeated measures ANOVA revealed that the
main effect of sex (F(1, 56) = 16.94, p < 0.001) and drug
treatment (F(3, 56) = 21.27, p < 0.0001) were both signifi-
cant for the 24-h food consumption. There was no inter-
action between these two factors (F(3, 56) = 0.3711, p >
0.1). Furthermore, the 24-h food intake was also un-
affected after combined Ex4 and MPPd treatment com-
pared to Ex4 alone and was still significantly reduced
compared to controls (one-way ANOVA, F(3, 28) =
9.905, p < 0.001; Fig. 6b and F(3, 28) = 12.83, p <
0.0001; Fig. 6d, for males and females, respectively). Two
male and two female rats did not finish the study due to
dislodged or blocked cannula.
Discussion
Preclinical research unraveling the neural basis of feed-
ing behavior is almost exclusively conducted in male
subjects, although recent evidence suggests females and
males may regulate feeding behavior differently [4–6].
Likewise, reward-mediated behavior may be differentially
regulated between men and women due to the impact of
sex hormones [40, 41]. GLP-1 agonists have previously
been shown to affect food intake and food-reward be-
havior [27, 29, 42, 43]. The current study provides
evidence that Ex4, the long-lasting GLP-1 analog, may
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have differential effects on food-reward in male and
female subjects. Moreover, we demonstrate that signal-
ing via central ER is necessary for the full impact of Ex4
on food reward. More specifically, signaling at the ERα
may be crucial, since selective ERα-antagonist, MPPd,
attenuated Ex4-induced food reward suppression.
Central GLP-1R agonist injection potently reduced
food-motivated behavior in females and males in a sex-
dependent manner in a progressive ratio operant condi-
tioning task. The progressive ratio operant conditioning
task, used here to analyze reward behavior, measures the
motivation to obtain a food reward. Food-reward behav-
ior is typically divided into two components: liking and
wanting, where liking is typically associated with the im-
mediate experience the moment a palatable food is con-
sumed, while wanting is associated with reward seeking
Fig. 4 Effect of central estrogen blockade on the actions of Ex4 on peanut butter consumption or chow intake is not divergent between the
sexes. No significant changes in peanut butter consumption were observed in males (a), but a significant reduction in consumption was noted in
females after injection of Ex4 or Ex4 and ICI (c). Ex4 reduced chow intake in both males and females (b, d). This reduction was attenuated by
simultaneous ICI treatment only in females. Chow and peanut butter consumption are displayed in grams. Data are expressed as mean ± SEM.
n = 10 (females) and 9 (males) per treatment group for peanut butter measurement and n = 10 (females) and 18 (males) per treatment group for
chow intake. *p < 0.05, ***p < 0.001
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Fig. 5 (See legend on next page.)
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(See figure on previous page.)
Fig. 5 Central injection of the ERα-antagonist MPPd attenuated the effects of Ex4 on food-motivated behavior. As expected, central administration of Ex4
led to a reduction in sucrose rewards earned in females (c) and males (a). Ex4 no longer significantly reduced sucrose rewards earned after administration
of the specific ERα-antagonist MPPd. Additionally, Ex4 treatment reduced lever presses for sucrose earned in females (d) and produced a trend for
reduction in males (b), an effect which was also attenuated by co-treatment with MPPd. Compilation of female and male data revealed a significant
reduction in sucrose rewards earned (e) and active lever presses (f) after EX4 treatment that was attenuated after combined MPP/Ex4 treatment. Data
are expressed as mean ± SEM. n = 7–9 for males and females. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 6 MPPd treatment did not attenuate the effects of central Ex4 treatment on food intake. Central injection with the GLP-1R agonist Ex4
significantly reduced peanut butter intake and chow intake in males (a, b) and females (c, d). The reduction was still present after treatment with
the ERα-antagonist MPPd. Chow and peanut butter consumption are displayed in grams. Data are expressed as mean ± SEM. n = 7–9 for males
and females. **p < 0.01, ***p < 0.001
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and an increased motivation to obtain rewarding foods
[23]. Here, we show that the wanting component of the
food-reward suppressing effects of Ex4 displays differen-
tial sensitivity in male and female rats. The actions of
Ex4 on food reward were also accompanied by a reduc-
tion in palatable food intake in females and males com-
pared to controls. However, peanut butter consumption
response to Ex4 was not significantly different between
male and female subjects. Progressive ratio test and pal-
atable food intake may to some extent represent the two
different aspects of food reward, where operant condi-
tioning mainly measures wanting, while peanut butter
intake better reflects the liking aspect of food reward.
The differences in sensitivity to Ex4 treatment between
sexes, therefore, seem to be specific to food-motivated
behavior. Though, it is important to note that consump-
tion of peanut butter is not a “pure” test of liking as it
allows for ingesting ad libitum amounts of the palatable
food; thus, an interaction with satiation signaling cannot
be discounted.
Our data clearly indicate differences in the sensitivity
to the food reward impact of Ex4 between females and
males. Interestingly, only females showed a significant
reduction in active lever presses, and sucrose rewards
earned, in the non-food deprived state after Ex4 treat-
ment. Yet, Ex4 has previously been shown to reduce
food-motivated behavior and reduce the intake of palat-
able foods in males [27, 44]. However, considering that
the preceding studies were conducted in rats that were
food-restricted during training, and typically also testing
in the progressive ratio task, in contrast to this experi-
ment, the absence of reward reduction in males may in-
dicate that Ex4 effect on food reward may be dependent
on feeding state. A recent report indicates that a single
overnight fast can attenuate GLP-1’s suppressive effect
on food intake. [45]. Here, we show similar results for
the GLP-1 agonist, Ex4, as unrestricted access to chow
resulted in a more potent reduction in chow intake after
GLP-1R agonist treatment. For reward behavior, the
interaction with fasting differs: overnight food restriction
led to a significant reduction in sucrose rewards earned
in male subjects after Ex4 administration. This effect
was still less potent than in females, further indicating a
higher sensitivity to Ex4 in female subjects. Baseline
measures for reward slightly differed between sexes, with
females receiving a larger quantity of rewards after ve-
hicle treatment. The differential baseline values may
cause some difficulty when comparing the effects of Ex4
in each sex since the higher baseline values displayed in
females may make small reductions in reward caused by
the drug more apparent. However, Ex4 treatment still re-
duced sucrose rewards earned in the food-restricted fe-
males to a larger extent than in food-restricted males,
even though here the baseline values of rewards earned
are not significantly different between the sexes. This
further supports the hypothesis that females are more
greatly affected by Ex4 treatment than their male
counterparts.
Sex differences in reward were not accompanied by
differences in overall food intake, indicating a potential
selectivity of the sex differences to reward. The clear im-
pact of Ex4 treatment on food intake suggests that the
drug was in fact also effective in males, as expected
based on previous studies with this agonist. However,
the long-term interaction of estrogens with GLP-1 in
women, including potential resulting sex differences in
body weight, requires further investigation. Our results
clearly suggest that when food availability is limited by
the amount of work/effort the animal has to put in to
obtain the food, Ex4 is much more efficient at reducing
this type of behavior in females. Since food is rarely
freely available to animals in nature, this effort-based
eating behavior is likely very relevant to natural eating
behavior. Surprisingly, only a few studies have looked at
potential differences in food reward regulation between
sexes in humans, though a recent study revealed differ-
ential connectivity in areas of the brain regulating re-
ward between men and women which may indicate that
food-reward behavior is differently regulated between
sexes [46]. Recently, several studies investigated the
effects of GLP-1R agonists on food intake and reward,
and activation of intake or reward-controlling CNS areas
in humans [47–49]; however, sex or gender interaction
was not the focus, and therefore, sex was either not
reported or the effect of sex not analyzed.
While the ability of estrogens to increase the potency
of Ex4 in both sexes is unexpected, it is in line with one
previous study indicating that co-administration of a
GLP-1 and estrogen agonist in a conjugated form, that
activates cells expressing estrogen receptors and GLP-
1R, or GLP-1R alone, reduces food intake and body
weight at doses of the hormones that are ineffective
alone [50]. Importantly, the reduction was comparable
in both sexes, suggesting that females and males benefit
from the enhancing effects of estrogens on GLP-1 ac-
tion. These data combined with current findings suggest
that estrogens’ signaling is sufficient to enhance food
intake in both sexes but does not seem necessary for the
anorexic effect of Ex4.
Estrogen receptors and GLP-1R are co-localized in
areas involved in reward behavior regulation such as the
VTA and the NAc [26, 51]. To our knowledge, little is
known about the role of estrogens in food reward,
though estradiol treatment in ovariectomized females
was previously shown to reduce the intake of palatable,
high-fat/high-sugar foods, in addition to reducing intake
of standard food [52]. The role of GLP-1R activation in
reward, however, is well-supported by recent literature
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[27, 29, 44], though studies investigating the food-
reward-mediated effects of GLP-1 have previously been
conducted exclusively in males [27, 31, 53, 54]. Nonethe-
less, estrogens have been shown to cause functional
changes in GABAergic neurons in the VTA and
dopaminergic terminals within the striatum [55, 56], and
estrogen treatment enhances striatal dopamine release
[55, 57–61]. Furthermore, estrogens induce increased
dopaminergic sensitivity to cocaine in ovariectomized
rats [61]. In addition, administration of estradiol during
the follicular phase increases the subjective effects of
amphetamine [62]. Levels of dopamine, its metabolites
and synthesizing enzymes, and amphetamine-induced
dopamine release vary as a function of the ovarian cycle
stage [57, 63]. Women progress faster to cocaine
dependence and display a higher incidence of relapse;
female rats also display a higher preference for cocaine
rewards, potentially due to the effects of estrogens
[40, 41]. In contrast, gonadectomy and sex hormone
treatments in males do not have a large impact on
cocaine-reinforced behaviors [64, 65]. Thus, while the
food reward impact of estrogens is unknown, the litera-
ture at least suggests its impact on drug reward. Past
studies focus on the rewarding effects of drugs of abuse
where estrogens mainly enhance reward in contrast to the
current results where estrogens reduced food reward by
enhancing effects exerted by GLP-1. Interestingly, it has
previously been reported that women report higher levels
of craving to rewarding foods, such as chocolate; these
cravings were reported to be most persistent during the
periods of the menstrual cycle characterized by low circu-
lating levels of estrogens [66] indicating that estrogens
may indeed reduce food reward, in contrast to their effects
on drug reward.
Current experiments utilizing ICI, a nonselective ER
antagonist, revealed that estrogens may increase the sen-
sitivity to Ex4 effects on reward. Estrogens’ effects on
food intake may be due to its ability to modulate the ac-
tivity of endogenous hormones [4, 5]. Thus, surprisingly,
the impact of estrogens on the anorexic action in the
case of insulin is opposite to that previously seen for
leptin and currently revealed for Ex4. Collectively, these
studies illustrate estrogen’s ability to modulate feeding
behavior by acting on appetite-regulating hormones.
Therefore, we hypothesized that estrogens may also play
a role in the differential sensitivity displayed by males
and females after Ex4 treatment. As hypothesized, cen-
tral treatment with the ERα (Esr1) and ERβ (Esr2) recep-
tor antagonist, ICI, attenuated the food reward effects of
Ex4 in females, but surprisingly, food-reward behavior in
males was also attenuated by ER blockade. Past literature
suggests that ERα is involved in homeostatic feeding
and weight regulation, and deletion of ERα leads to
obesity in both sexes in mice [67, 68]. In addition,
administration of estradiol reduces food intake and pre-
vents weight gain in wild-type, but not in ovariectomized
transgenic mice lacking ERα, further indicating a role for
ERα in homeostatic feeding [69, 70]. Previous studies
have mostly failed to find a connection between ERβ and
feeding behavior [69, 70]. In contrast, selective activation
of ERβ receptor was even shown to increase cocaine-
seeking behavior, an effect that was not seen after ERα
receptor stimulation, indicating that ERβ may affect
reward-related behavior [71]. Thus, ERβ was an unlikely
interaction target. Consistent with this idea, the selective
ERα-antagonist MPPd was sufficient to attenuate the ef-
fects of Ex4 on reward, in both males and females, indi-
cating that signaling via the ERα may be necessary for
Ex4 impact on food-reward behavior. Though it is im-
portant to note that while MPPd is classified as an ERα
antagonist and has been shown to antagonize estrogen-
regulated genes in vitro and attenuate estrous-related
decreases in food intake [72, 73], it has also been sug-
gested to have estrogen-like activity since it increased
uterine weight in rodents and reduced food intake in
OVX rats [73]. Our data do not eliminate the possible
involvement of ERβ, or other ER, such as GPR30. It is
also possible that other gonadal steroids may be behind
these differences. Testosterone, for example, regulates
insulin sensitivity [74, 75]. However, in contrast to ovari-
ectomy, orchiectomy decreases daily food intake and
body weight by decreasing meal frequency, an effect
which can be reversed by testosterone treatment [76, 77].
Potential effects of testosterone on Ex4 actions on food re-
ward are yet to be investigated. Importantly, substances
other than sex steroids may also be involved.
Although females have higher estrogen levels than
males, males also possess a certain level of circulating
estrogens due to the conversion of testosterone to estro-
gen, by the enzyme aromatase, in the reproductive tract,
bone, and adipose tissue [78]. Since premenopausal fe-
males have much higher levels of circulating estrogens,
the increased impact of Ex4 in females shown here may
result from these elevated levels of estrogens. However,
since estrogens can enhance the action of GLP-1 on
food intake in males [50] and blockade of ER signaling
reduces the impact of GLP-1R activation on food reward
in males, even low levels of estrogens in males may be
sufficient to increase the sensitivity to GLP-1. Moreover,
the estrogen synthesis enzyme aromatase is also present
in the brain, mainly in neurons in the hypothalamus and
limbic system [79]. In addition, the anorexigenic effects
of estradiol have previously been attributed to its actions
within the CNS as only central but not peripheral block-
ade with ICI increases food intake [38]. Thus, it is pos-
sible that the small amounts of estrogens synthesized by
the male brain are also sufficient to play an important
role in the reward effects of GLP-1. It is even possible
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that brain-synthesized estrogens may function as a po-
tential downstream mediator of GLP-1 effects, an idea
ripe for future studies.
The current study provides novel evidence for the
effects of the synthetic GLP-1R agonist Ex4 on food-
motivated behavior in females and its interaction with
central estrogen signaling, but it also has some limita-
tions. Here, for reasons described above, only central
Ex4 application was used in contrast to the peripheral
administration utilized during clinical treatment with
these agonists. However, both GLP-1 and Ex4 have been
shown to cross the blood-brain barrier [35, 80], and
feeding or reward impact of Ex4 is mediated by CNS
GLP-1R, indicating that GLP-1 agonists are likely to re-
sult in sex differences even after peripheral injection. In
addition, the potential food-reward suppressing effects
of endogenously produced GLP-1 may differ from those
found here for Ex4; thus, the results here are more
directly relevant to the clinically used GLP-1 analog, and
the relevance to endogenous GLP-1 should be a topic
for future investigation.
Conclusions
These data indicate that there are sex differences in the
sensitivity to the food reward effects of Ex4. Moreover,
signaling through the ERα is essential for the reward-
reducing impact of Ex4. Synthetic GLP-1 analogs are
widely used in the clinic as a treatment for type-2
diabetes, and one was also recently approved as a
supplement for weight-management [81]. Although
these drugs are prescribed to individuals of both sexes,
preclinical studies have almost exclusively been done in
male subjects, a concern which is present throughout
many scientific fields. Moreover, these drugs have the
ability to cross the blood-brain barrier and exert the ef-
fects evaluated here through their actions on the CNS.
Data presented here may indicate a higher sensitivity to
these substances in women. If our findings will be repli-
cated in a future clinical study, then physicians prescrib-
ing this medication may need to consider establishing
alternative doses for female patients taking these drugs.
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